Relevant conflict of interest/financial disclosures: Dr. Hauser has received fees from Teva Pharmaceuticals for consulting, advisory board participation, and speaker programs. Although clinical trials of rasagiline were analyzed in this study, Teva Pharmaceuticals was not involved and did not sponsor this study.
Determination of minimal clinically important change in early and advanced Parkinson's disease†
Article first published online: 24 MAR 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 5, pages 813–818, April 2011
How to Cite
Hauser, R. A., Auinger, P. and on behalf of the Parkinson Study Group (2011), Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov. Disord., 26: 813–818. doi: 10.1002/mds.23638
This data-mining project was supported by the Parkinson's Disease Foundation's Advancing Parkinson's Treatments Innovations Grant to the Parkinson Study Group.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 21 APR 2011
- Article first published online: 24 MAR 2011
- Manuscript Accepted: 22 NOV 2010
- Manuscript Revised: 14 NOV 2010
- Manuscript Received: 23 JUL 2010
- Parkinson's Disease Foundation's
- Parkinson Study Group
|MDS_23638_sm_authorroles.doc||25K||Author Roles and Disclosures|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.